leisure time -WSS

leisure time

author：knowledge 2025-09-06 04:50:51 - browse：3129

A syringe is prepared at a clinic in Norristown, Pa., Dec. 7, 2021. The Environmental Protection Agency finalized a rule Thursday, March 14, 2024, imposing stricter limits on a chemical used to sterilize medical equipment after finding a higher-than-expected cancer risk at facilities that use ethylene oxide to clean billions of devices including catheters and syringes. ( — The agency first proposed limits on the gas in April 2023, with the goal of reducing emissions by 80%. Now, the agency is predicting an emissions reduction of 90%. Matt Rourke/Ap

On Thursday, the Environmental Protection Agency finalized limits on a carcinogenic gas called ethylene oxide that is used to sterilize most medical devices. Sterilizing facilities had polluted the air unchecked for decades, leading to disproportionately high cancer risks in surrounding communities.

The agency first proposed limits on the gas in April 2023, with the goal of reducing emissions by 80%. Now, the agency is predicting an emissions reduction of 90%. The rule will require commercial sterilization facilities to monitor and submit proof of their reduced emissions. It aligns with the Biden administration’s greater mission to end cancer and commitment to environmental justice, the EPA said.

Ethylene oxide is the most frequently used sterilizing chemical for devices that can’t be exposed to steam. It’s used to sanitize 20 billion devices in the U.S. per year, such as pacemakers, catheters, and ventilators. But long-term exposure to the gas can cause breast cancer, non-Hodgkin’s lymphoma, lymphocytic leukemia, and myeloma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Chamber of Commerce, DOJ clash in court over drug prices

entertainment

WSS

Patients, doctors press FTC to beef up hospital merger scrutiny

Merck to acquire Harpoon Therapeutics for $680 million

FDA early review: GLP

Why the drug industry's warnings on the IRA's impact fall short

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Why the drug industry's warnings on the IRA's impact fall short

hotspot

leisure time

focus

Virginia high school admissions case could be legal follow

Medicare Advantage coverage denials need scrutiny, senators say

Medicare details structure of new drug price negotiation program

Akili changes sales model for its ADHD video game treatment

Bright Health sells Medicare Advantage business to Molina

A preacher's new calling: Diversifying neuroscience research

Novavax promises a turnaround & Lilly roils the obesity market

Study suggests new cause of Down syndrome: cells linked to aging

What does generative AI mean for health care? We asked experts

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

focus

Fed up with FDA, ALS advocates consider a take

Medicare to pay more for cardiac rehab in hospital outpatient clinics

FDA panel to weigh safety of artificial wombs for preterm births

David Liu startup to focus on CRISPR delivery

Patients, doctors press FTC to beef up hospital merger scrutiny

Why the quest to eradicate polio has stumbled

hotspot

focus

entertainment

explore